A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NCT00157872
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
A study to compare rofecoxib versus naproxen in the treatment of Chinese patients with rheumatoid arthritis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- Chinese males or females at least 18 years of age with rheumatoid arthritis
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method patient's global assessment of disease activity investigator's global assessment of disease activity Tender joint count swollen joint count
- Secondary Outcome Measures
Name Time Method patient's global assessment of response to therapy investigator's global assessment of response to therapy Patient pain assessment
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of rofecoxib in rheumatoid arthritis compared to naproxen?
How does rofecoxib's COX-2 inhibition compare to naproxen's COX-1/COX-2 inhibition in RA treatment outcomes?
What biomarkers correlate with response to rofecoxib versus naproxen in Chinese RA patients?
What adverse events were observed in NCT00157872 and how do they compare to other COX-2 inhibitors?
How does rofecoxib's efficacy in RA compare to other NSAIDs like celecoxib or diclofenac in post-marketing studies?